Pomalive, a Standardized Olive and Pomegranate Extract Formulation, May Support Dyslipidemia, Recent Study Finds

A recent study1 found that supplementation with a product combining a standardized extract of olive and a standardized extract of pomegranate (Pomalive from Euromed, based in Mollet del Vallès, Spain), can promote dyslipidemia. The product contains hydroxytyrosol from olive and punicalagin from pomegranate, which are polyphenols that research has shown to support endothelial function. The study was conducted by researchers from the Department of Nutrition at the University Hospital of La Paz, based in Madrid, Spain.

In the twenty-week randomized, double-blind, placebo-controlled, crossover clinical trial, 84 subjects aged 45 to 65 with dyslipidemia received either Pomalive or placebo for two eight-week treatment periods, separated by a four-week weaning period. period. At the beginning and end of each 8-week intervention period, fasting blood samples were collected for biochemical analysis of total cholesterol, high-density lipoprotein cholesterol (HDL-C), low density lipoproteins (LDL-C) and triglycerides.

Results showed that active supplementation significantly reduced plasma LDL-C levels in subjects with baseline elevated plasma LDL-C levels (≥ 160 mg/dL). No significant effect was found after placebo. At the end of the placebo period, subjects experienced a significant decrease in plasma HDL-C levels, while Pomalive supplementation resulted in a significant increase in plasma HDL-C levels in subjects with initially low plasma levels of HDL-C. Pomalive supplementation also significantly reduced plasma TG levels, while placebo had no effect on plasma TG levels.

“In an increasingly aging society that struggles with lifestyle diseases such as [atherosclerotic vascular disease], we consider our natural product, produced in a sustainable way and of high purity, as a real contribution to improving the quality of life in the years to come,” said Andrea Zangara, head of scientific marketing at Euromed, in a press release. Press. “The study results, obtained using gold standard protocols and in collaboration with an authoritative medical institution, provide further evidence on the benefits of Pomalive for cardiovascular health, making it an ideal inclusion in dietary supplements, functional foods and high-end pharmaceuticals.

Reference

  1. Quirós-Fernández, R et al. “An oral supplement containing hydroxytyrosol and punicalagin improves dyslipidemia in an adult population without coadjuvant therapy: a randomized, double-blind, controlled, crossover trial.” Nutrients, flight. 14, no. 9 (2022 Apr 29): 1879, https://doi.org/10.3390/nu14091879

Comments are closed.